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Intestinal microbiota development 
and gestational age in preterm 
neonates
Katri Korpela1,2, Elin W. Blakstad3,4, Sissel J. Moltu5, Kenneth Strømmen4,6, Britt Nakstad3, 
Arild E. Rønnestad6,7, Kristin Brække5, Per O. Iversen4,8, Christian A. Drevon4 &  
Willem de Vos1,9
The intestinal microbiota is an important contributor to the health of preterm infants, and may be 
destabilized by a number of environmental factors and treatment modalities. How to promote the 
development of a healthy microbiota in preterm infants is largely unknown. We collected fecal samples 
from 45 breastfed preterm very low birth weight (birth weight < 1500 g) infants from birth until 60 days 
postnatal age to characterize the intestinal microbiota development during the first weeks of life in 
preterm infants. Fecal microbiota composition was determined by 16S rRNA amplicon sequencing. The 
main driver of microbiota development was gestational age; antibiotic use had strong but temporary 
effects and birth mode had little influence. Microbiota development proceeded in four phases indicated 
by the dominance of Staphylococcus, Enterococcus, Enterobacter, and finally Bifidobacterium. The 
Enterococcus phase was only observed among the extremely premature infants and appeared to delay 
the microbiota succession. The results indicate that hospitalized preterm infants receiving breast milk 
may develop a normal microbiota resembling that of term infants.
Prematurity is a risk factor for infant morbidity and mortality1, and is associated with a high risk of bacterial and 
inflammatory diseases, such as sepsis and necrotizing enterocolitis (NEC). Preterm infants have an immature 
intestine with underdeveloped peristalsis, barrier function and immunity, which makes the intestine a potential 
source of infections and inflammation2,3. Several studies have shown that the intestinal microbiota in preterm 
infants differ from that of healthy term infants4–11. Common anomalies are the bloom of opportunistic and poten-
tially pathogenic bacteria such as Enterobacter, Enterococcus, and Staphylococcus4–7. Many common practices, 
caesarean section12–14, antibiotic use15, and formula feeding14–16, may disrupt normal microbiota development. 
Moreover, studies with small groups of infants have indicated that both NEC and late-onset sepsis are associated 
with alterations in the microbiota8–11, and that the microbiota composition correlates with signs of pain and 
distress17. Modification of the microbiota by probiotics or breast milk may reduce the risk of NEC in preterm 
infants18,19. Thus, promoting a healthy microbiota development in preterm infants is important, and a key ques-
tion is whether natural colonization and succession of the microbiota is possible in these infants. For rational 
decision-making and consideration of therapies in the future, information on the microbiota development in 
preterm infants is essential. Although studies on the preterm microbiota have been conducted4–11, they involve 
only a handful of infants and none show detailed microbiota succession.
To establish a defined and predictive picture of the preterm infant microbiota development, we analyzed 262 
fecal samples from 45 preterm infants using deep 16S rRNA amplicon sequencing.
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Methods
Study design and participants. The samples were collected during a randomized controlled trial con-
ducted in 2010 at Akershus and Oslo University Hospitals, Norway. The study was approved by the Regional 
Committee for Medical and Health Research Ethics, Norway (Reference number: 2009/1946) and performed 
in accordance with the principles of the Helsinki Declaration. Written informed consent was obtained from the 
parents. The study was registered in Clinical Trials (registration number NCT01103219) on 12. April 2010. The 
trial was designed to investigate the effect of enhanced nutrient supply to very low birth weight infants (VLBW; 
birth weight < 1500 g) as previously described20.
All VLBW infants born between August 17th and December 21st 2010 in the study hospitals were eligible for 
inclusion. Exclusion criteria were congenital malformations, chromosomal abnormalities, critical illness with 
short life expectancy and clinical syndromes known to affect growth and development. Infants were included 
after written informed parental consent was obtained and randomized into two nutrition groups within 24 h 
after birth. Fifty-seven infants were eligible for inclusion but 7 infants were not included due to parental consent 
refusal (1), critically sick mother/sibling (3), congenital anomaly (1) and omissions during enrollment (2). Thus, 
50 infants were included in the trial. Three infants died during the first weeks of life and two infants were excluded 
due to critical illness and congenital heart disease. Hence, 45 VLBW infants were included in the present study 
investigating the microbiota development. Twenty-four of these infants received enhanced nutrient supply, i.e. 
increased supply of energy, protein, fat, the long-chain polyunsaturated fatty acids (PUFA) and vitamin A20. 
Twenty-one infants were classified as extremely premature (EP) and 24 as moderately or very premature (MVP). 
Caesarean delivery was common, especially in the MVP group (Table 1).
Four types of antibiotics were given to the infants: aminoglycosides (gentamycin, N = 10) usually combined 
with ampicillin/ekvacillin (N = 26), and vancomycin (N = 6) usually combined with cephalosporin (N = 12). 
Ampicillin and cephalosporin were not given alone. The antibiotics were all given intravenously. Vancomycin 
was not given to any of the infants during the first 10 days of life.
Fecal sample collection. Fecal samples were collected from diapers at different intervals from birth until 
discharge from the hospitals (up to 60 days postnatal age). The median (range) number of samples per infant 
was 6 (2–11). Fresh samples were collected from diapers and frozen at −80 °C until analyzed. In total 262 fecal 
samples were analyzed.
16S rRNA amplicon sequencing and pre-processing. The microbiota composition of the fecal samples 
was analyzed using 16S rRNA amplicon sequencing with Illumina MiSeq. DNA was extracted using the repeated 
bead beating method, and for sequencing we used the V1-V3 primers forward AGAGTTTGATCMTGGCTCAG 
and reverse GTATTACCGCGGCTGCTG. The reads were processed and analyzed using the R-package mare21, 
which utilizes USEARCH22 for quality filtering, clustering of reads into species-like operational taxonomic units 
(OTUs), and taxonomic annotation. The analysis procedure was validated using artificial microbial communities 
of known composition21. Specifically, we assessed how the observed microbiota composition depended on read 
length. We found that the forward reads trimmed to 100–150 nucleotides resulted in better correspondence to 
the actual composition in the artificial communities than using long, merged paired-end reads (Supplementary 
Fig. 1). Thus, we used only the forward reads, which we truncated to 150 nt, to remove low-quality bases at the 
end of the reads. The 150nt reads were quality-filtered. All sequences representing less than 0.001% of the total 
EP n = 21 MVP n = 24 P
GA, wk, median (IQR) 26 (25.1–27.2) 30.0 (29.0–31.2) <0.001
BW, median (IQR) 830 (727–990) 1205 (1009–1302) <0.001
BW z-scores, median (IQR) −0.5 (−1.2–0.2) −1.1 (−1.9–0.8) <0.01
SGA, n (%) 11 (46%) 4 (19%) 0.07
Boys, n (%) 12 (57%) 17 (71%) 0.34
C-section, n (%) 12 (57%) 21 (88%) 0.04
Prenatal steroid exposure, n (%) 20 (95%) 23 (96%) 1
Apgar 1 min, median (IQR) 5.0 (3.0–7.5) 7.5 (6.0–8.8) <0.01
Apgar 5 min, median (IQR) 7.0 (6.0–8.0) 8.5 (6.0–9.0) 0.03
Respirator days, median (IQR) 11.0 (2.5–31.5) 0 (0–2.8) <0.001
Oxygen dependency at 36 w PMA, n (%) 10 (50%)* 0 (0%) <0.001
Late-onset sepsis, n (%) 16 (76%) 6 (25%) 0.001
IVH grd ≥ 3, n (%) 3 (14%) 1 (4%) 0.33
NEC, n (%) 2 (10%) 0 (0%) 0.21
PDA treatment (medical/surgical), n (%) 9 (45%) 0 (0%) <0.001
ROP (grd III/+disease), n (%) 4 (20%)* 0 (0%) 0.04
Table 1. Characteristics of the extremely premature (EP) and moderately/very premature (MVP) infants. Data 
are presented in number (percentages) or median (IQR), *n = 20. BW = birth weight; C-section = Cesarean 
section; EP = Extremely premature; GA = gestational age; IQR = interquartile range; IVH = intraventricular 
haemorrhage; MVP = moderate or very premature; NEC = necrotizing enterocolitits; PDA = persistent ductus 
arteriosus; PMA = post menstrual age; ROP = retinopathy of prematurity; SGA = small for gestational age.
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reads were eliminated, as rare reads are likely to contain errors or chimaeras. The reads were OTU-clustered for 
richness analysis. The OTUs were not annotated, as OTU-clustering is a potential source of taxonomic errors. 
Instead, we taxonomically annotated the reads. After quality filtering, we had on average 68 000 reads per sample, 
ranging from 23 to 282 000. The samples with <100 reads were meconium samples, in which very low abun-
dance of bacteria is expected, and therefore we considered the low number to be biologically relevant. For the 
meconium samples we obtained on average 26 000 (23–98 570) reads. We included also 14 empty samples as neg-
ative controls in the sequencing run. The number of reads obtained for these samples varied between 0 and 822 
(median = 37, mean = 164). We compared the composition observed in the meconium samples with <1000 reads 
to that in the negative control samples (Supplementary Fig. 2). Four of the meconium samples had control-like 
compositions high in lactobacilli, suggestive of contamination. These few meconium samples were unlikely to 
alter the results, and they were kept in the analysis.
Statistical analyses. The statistical analyses were conducted using the R package mare21, which implements 
tools from the R package vegan23. Principal coordinates analysis (PCoA), which summarizes the multivariate 
microbiota data into a few variables, was conducted using Bray-Curtis dissimilarities with the R-package vegan23. 
Associations between the most abundant bacterial groups with the host factors postmenstrual age, postnatal age, 
and birth mode (vaginal/cesarean) as well as antibiotic courses (aminoglycoside or vancomycin) were tested using 
generalized additive mixed models (GAMM), with negative binomial error distribution (function gam in the 
package mgcv24), subject ID as the random variable, and the number of reads as the offset.
Data availability. The data are available in Supplementary Table 1. The DNA sequences will be submitted to 
European Nucleotide Archive (http://www.ebi.ac.uk/ena).
Term infant samples. To compare the microbiota development in the premature infants to the microbiota 
in term-born healthy infants, we included previously reported 16S rRNA–based microbiota composition data 
from a Dutch infant cohort25 in which 9 fecal samples were collected from 187 infants during the first 15 postnatal 
weeks (total 665 samples).
Results
Development of microbiota in preterm infants. The intestinal microbiota composition in the 45 pre-
mature neonates was longitudinally followed and was characterized by strong dominance of only a few organ-
isms. Typically one of four genera, Bifidobacterium, Enterobacter, Staphylococcus or Enterococcus, represented 
>50% of the reads in a given sample (Supplementary Fig. 3, Fig. 1a). The infants often switched from one pattern 
of microbiota (dominating organism) to another within days (Supplementary Fig. 3). The overall microbiota 
composition was strongly associated with postnatal age (Fig. 1b, R2 = 0.07, p = 0.001 in permutational multivar-
iate ANOVA) and even more clearly with postmenstrual age (Fig. 1c, R2 = 0.13, p = 0.001). After adjusting for 
postmenstrual age, postnatal age explained only 2% of the variation (p = 0.002). With increasing postmenstrual 
age, the infants progressed from Staphylococcus-Enterococcus-dominated composition to Enterobacter and finally 
towards Bifidobacterium-dominated microbiota (Fig. 1c).
We compared the observed microbiota composition at different postnatal ages in the EP and MVP infants to 
healthy term-born infants. The microbiota composition in the preterm infants progressed towards the compo-
sition observed in the term-born infants, depending on gestational age (Fig. 1d); the microbiota development in 
the EP group appeared to lag behind that of the MVP group (Fig. 1d), but the development was matched in both 
groups when considering the postmenstrual age. In fact, when comparing the MVP and the term infants at the 
same postmenstrual age, it appeared that the microbiota of the MVP infants progressed faster towards a strongly 
Bifidobacterium-dominated composition (Fig. 1d).
To assess the development in bacterial load with age, we measured the total DNA concentration in the 
fecal samples (Fig. 1e). For further insight, the DNA yield was subdivided to different bacterial taxa based on 
their relative abundances. The amount of DNA in the samples was fairly stable until 30 weeks postmenstrual 
age, after which it began to increase, possibly due to an increase in the absolute abundance of bifidobacteria. 
Simultaneously, the absolute abundance of staphylococci and enterococci appeared to decline. After 36 weeks 
postmenstrual age, there appeared to be a decline in DNA yield, as bifidobacteria became dominant and all other 
bacteria declined.
Overall, the DNA concentration increased significantly with postmenstrual age (Fig. 2a, p = 0.03, explaining 
14% of the variation), and with postnatal age (Fig. 2b, p = 0.0002, 7% of the variation), indicating an increase in 
total bacterial abundance, and therefore active replication. The DNA concentration was not dependent on birth 
mode (p = 0.8, 0.1% of variation).
Simultaneous with the increase in DNA concentration, richness of the microbiota increased with postmen-
strual age (Fig. 2a, p = 0.0014, explaining 20% of the variation), and with postnatal age (Fig. 2b, p = 0.02, 7% of the 
variation). Richness was not associated with birth mode (p = 0.19, 1% of the variation). The microbiota develop-
ment with age was captured by the sum of the score on the first two principal coordinates (Fig. 1a–c). We used the 
PCoA score sum as the development index. This index was positively associated with postmenstrual age (Fig. 2c, 
p < 0.0001, 35% of the variation), but after adjusting for postmenstrual age, the association with postnatal age was 
not significant (Fig. 2d, p = 0.4, 1% of the variation). The development index tended to be lower in vaginally born 
infants (p = 0.07, 1% of the variation).
Microbiota development in phases. A detailed analysis of the most abundant genera revealed that the 
development of the microbiota composition was not random, but followed a pattern depending on postmenstrual 
age (Fig. 3). The gestational age at birth appeared to have little influence on the microbiota development, as the 
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EP, MVP, and healthy term-born infants followed largely the same course of development. In the first 50 weeks 
postmenstrual age, there were four successional phases.
Phase 1 was Staphylococcus dominance, which peaked between 25 and 30 weeks postmenstrual age and ended 
by 35 weeks postmenstrual age, and therefore did not occur in term-born infants (Fig. 3a). The abundance of 
Staphylococcus was significantly associated with postmenstrual age (p < 0.0001), which explained 20% of the var-
iation in Staphylococcus abundance, while postnatal age explained an additional 8% of the variation (p < 0.0001). 
Vaginally born infants had a higher abundance of Staphylococcus, although birth mode explained only 1% 
Staphylococcus abundance (p = 0.004). Individuality covered 8% of the variation in Staphylococcus (p = 0.016).
Phase 2 was Enterococcus dominance, peaking at 30 weeks and ending by 35 weeks postmenstrual age 
(Fig. 2b). Postmenstrual age explained 3% of the variation in the abundance of enterococci (p = 0.0001), and 
postnatal age explained 2% (p = 0.002). Birth mode was not significantly associated with the relative abundance 
of Enterococcus (p = 0.74). Enterococcus abundance showed high individuality, subject ID explaining 30% of the 
variation (p < 0.0001).
Phase 3 was Enterobacteriaceae dominance (mainly genus Enterobacter in the preterm infants), peaking on 
average at 35 weeks postmenstrual age (Fig. 2c). The term-born infants showed only the declining part of this 
successional phase. There appeared to be a modest secondary bloom of enterobacteria at 45–50 weeks post-
menstrual age. Among the preterm infants, the timing of the Enterobacter peak showed extensive individual 
variation and consequently the postmenstrual age explained only 1% of the variation (p = 0.47), and postnatal 
age explained 4% (p = 0.22). Vaginal birth was associated with lower abundance of Enterobacter (p = 0.01, 1% of 
variation explained).
Phase 4 was characterized by a high abundance of Bifidobacterium, which began to develop gradually after 
30 weeks postmenstrual age. Postmenstrual age explained 11% of the variation in Bifidobacterium abundance 
(p < 0.0001), and postnatal age explained 5% (p = 0.39). There was considerable individuality in Bifidobacterium 
abundances, ID explaining 24% (p < 0.0001), while birth mode explained 1% (p = 0.22).
Associations between microbiota and antibiotic treatments. To assess the effect of antibiotic treatments on 
the microbiota, we focused on the period before and after antibiotic courses, and estimated the effect of 
Figure 1. Microbiota composition in the fecal samples of preterm infants. Principal coordinates analyses 
(PCoA, Bray-Curtis dissimilarities) (a–c). The axes represent PCoA component scores, showing the two most 
important gradients differentiating the microbial communities. Each circle represents a microbial community, 
colored in panel (a) by the dominant organism in the community (>50% of all reads). Background color 
corresponds to: (b) postnatal age of the infant at the time of fecal sample collection; (c) postmenstrual age of 
the infant at sample collection. Blue background indicates low values, green intermediate, and orange high 
values. Average relative abundances of the dominant families in extremely premature (EP), moderately or very 
premature (MVP), compared to term infants from a Dutch cohort, at different postmenstrual ages (weeks)25 
(d). Average total DNA concentration by postmenstrual age, divided to bacterial taxa based on their relative 
abundances in the 16S rRNA data (e).
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aminoglycoside and vancomycin antibiotics after adjusting for postmenstrual age, postnatal age, and birth mode. 
The responses to the antibiotics were generally temporary and the microbiota appeared to recover within days 
(Fig. 4, Supplementary Fig. 4). Furthermore, only a subset of the infants responded to the antibiotics, show-
ing lower than expected values during the first 10 days after the beginning of the antibiotic, while others either 
showed no response or even the opposite, increasing response.
In terms of total DNA, microbiota richness, and microbiota development index, 37% of the infants responded 
temporarily to aminoglycoside (Supplementary Fig. 4a,c,e). The rest either did not respond or showed a tempo-
rary increase in total DNA and development index (Supplementary Fig. 4a,e). Vancomycin treatment was associ-
ated with a decline in total DNA and development index in 52% of the infants, but richness was not significantly 
affected (Supplementary Fig. 4b,d,f).
Individual bacterial taxa did not always respond according to the total DNA response (Fig. 4). Staphylococcus 
and Enterobacter followed the same pattern as total DNA, showing a short-term response to aminoglycoside 
in 37% of the infants and to vancomycin in ca. 50%. Enterococcus showed a dramatic short-term decline in 
response to aminoglycoside in 56% of the infants, and increased in response to vancomycin in 74% of the infants. 
Bifidobacteria declined in 58% of the infants temporarily in response to aminoglycoside treatment. Vancomycin 
treatment was associated with either a short-term reduction of bifidobacteria, or a slower but persistent reduction.
Microbiota composition and sepsis incidence. Fourteen cases of sepsis in 10 infants were documented during 
the study period with fecal samples collected within five days of diagnosis. Based on blood cultures, the caus-
ative organisms of sepsis in the analyzed cases were always staphylococci. Staphylococcus was more abundant 
before sepsis than after (Fig. 5), and in 7/14 cases, Staphylococcus was dominant in the fecal samples either before 
or during sepsis. During sepsis, the dominant organism in the fecal samples was Enterobacter in five cases, 
Enterococcus in five cases, and Staphylococcus in four cases (Supplementary Fig. 2). Sepsis did not occur in infants 
with Bifidobacterium as the dominant organism; the abundance of Bifidobacterium was significantly reduced 
during sepsis (Fig. 5).
Discussion
We followed the development of the intestinal microbiota longitudinally in a cohort of 45 prematurely born 
infants from birth to discharge from hospital up to 60 days after birth. Frequent sampling enabled the detailed 
construction of individual developmental patterns, and characterisation of the microbiota succession. Our results 
show that the promotion of normal microbiota development in prematurely born infants is possible in a hospital 
setting, because many infants progressed to a Bifidobacterium-dominated composition which is characteristic 
Figure 2. Development of the microbiota with postmenstrual (a,c,e) and postnatal (b,d,e) age. Association 
between postmenstrual and postnatal age of the infant and total DNA concentration (a,b), microbial richness 
(c,d), and development index (e,f, sum of the two first principal components in Fig. 1) among infants born 
before (extremely premature, EP), and at/after gestational week 28 (moderately or very premature, MVP). The 
trend lines show the best-fit (second polynomial) and the shaded areas show 95% confidence intervals.
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of healthy term-born non-hospitalized infants. A major obstacle for the microbiota development among the 
extremely premature infants was the overgrowth of Enterococcus spp, which seemed to inhibit the normal succes-
sion by several weeks in some cases.
We found maturity, indicated by postmenstrual age, to be a major determinant of the microbiota develop-
ment, and particularly of the ability of bifidobacteria to reach dominance. This has previously been observed 
in term and premature infants26,27. Regardless of the gestational age at birth, infants began to proceed towards a 
Bifidobacterium-dominated composition, an indicator of healthy microbiota in infants, after postmenstrual week 
30. The results show that although the extremely premature infants had significantly more co-morbidities and 
required more medical interventions than the moderately premature group, both premature groups followed 
the same microbiota development pattern. This suggests that physical maturity is a very strong determinant of 
microbiota development in neonates.
In our cohort, infants with a disrupted microbial development, showing a dominance of aerobic cocci and 
reduced abundance of bifidobacteria, were at increased risk of sepsis. A dominance of Enterobacter spp. or other 
Proteobacteria, and the absence of bifidobacteria have previously been associated with risk of necrotizing enter-
ocolitis and sepsis in preterm infants8–11; in our cohort Enterobacter was abundant in some sepsis cases, but also 
in many cases not developing sepsis.
As the microbiota development is dependent on infant maturity, particularly the extremely premature infants 
are at risk of delayed microbiota development and may require therapeutic interventions. Supplementation 
with bifidobacteria or bifidogenic prebiotics has been shown to increase the abundance of bifidobacteria in pre-
term infants, to reduce the abundance of clostridia and enterobacteria, and to decrease signs of distress17,28,29. 
Antibiotics may have a harmful effect on the microbiota development30. In line with this, we observed temporary 
changes in microbiota composition following antibiotic courses. The microbiota appeared to recover within 2–3 
weeks. Importantly, the response to antibiotics depend on the susceptibility of the bacteria to the drug. For exam-
ple, vancomycin-resistant enterococci prevail in hospital environments, and may prevent a beneficial response.
Unlike most previous studies, our cohort included many infants with a fairly normal microbiota development, 
achieving high abundance of bifidobacteria. All infants in our study received human milk from the first days of 
Figure 3. Development of the most abundant bacterial genera in premature and term-born infants with respect 
to postmenstrual age. The trend lines show the best-fit (second polynomial) and the shaded areas show 95% 
confidence intervals.
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life. Breast milk feeding is known to increase the abundance of bifidobacteria in infants31,32. The increase in bifido-
bacteria was achieved also in caesarean-delivered infants, demonstrating that normal microbiota development is 
possible even in these prematurely born, hospitalized, caesarean-delivered infants. This suggests that the recently 
suggested practice of vaginal seeding33, i.e. swabbing the neonate with the mother’s vaginal fluids, which has been 
criticized as potentially risky34, is unnecessary if breast milk (from mother or donor) is given.
Our results suggest that normal-like microbiota development in preterm infants in the hospital setting is pos-
sible, particularly among moderately premature infants receiving breast milk. In the extremely premature infants, 
development appeared to be disrupted by persistently increased abundance of Enterococcus. Future research on 
interventions to improve the microbial colonization in extremely premature infants and infants with patterns 
indicating abnormal developmental patterns, could improve short- and long-term outcomes.
Figure 4. Effect of antibiotic treatments on the most abundant bacterial genera. Deviation from expected 
relative abundance of each genus, based on age of the infant and birth mode, is shown in relation to timing of 
the antibiotic courses. Consistently negative values after the beginning of the antibiotic course (between days 
1 and 10) are interpreted as a response to the antibiotic, and the infants are categorized as responders (blue) or 
non-responders (red). Number of infants in each category and the p-values of the GAMM models are shown.
Figure 5. Relative abundances of Bifidobacterium, Staphylococcus, and Enterococcus before (“Pre”), during 
(“Sep”), and after (“Post”) sepsis, compared to infants with no sepsis (“No”).
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